{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:47:15Z","timestamp":1782773235780,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Administration of Traditional Chinese Medicine - Liu Weisheng National Project for Famous and Experienced Traditional Chinese Medicine Practitioners","award":["2013KT1502"],"award-info":[{"award-number":["2013KT1502"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04262-7","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:54:48Z","timestamp":1778061288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rare transformation from small cell lung cancer to lung squamous cell carcinoma: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Hongxi","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanting","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"4262_CR1","unstructured":"National Comprehensive Cancer Network. (NCCN) Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer, Version 2. 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf. Accessed 16 Sep 2025."},{"issue":"6","key":"4262_CR2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619\u201330.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4262_CR3","doi-asserted-by":"publisher","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408.","journal-title":"ESMO Open"},{"issue":"23","key":"4262_CR4","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220\u20139.","journal-title":"N Engl J Med"},{"issue":"10212","key":"4262_CR5","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339.","journal-title":"Lancet"},{"issue":"5","key":"4262_CR6","doi-asserted-by":"publisher","first-page":"189413","DOI":"10.1016\/j.bbcan.2025.189413","volume":"1880","author":"S Liu","year":"2025","unstructured":"Liu S, Xu T, Cao X, et al. Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches. Biochim Biophys Acta Rev Cancer. 2025;1880(5):189413.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"4","key":"4262_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/JCO.18.01585","volume":"37","author":"N Marcoux","year":"2019","unstructured":"Marcoux N, Gettinger SN, O\u2019Kane G, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019;37(4):278\u201385.","journal-title":"J Clin Oncol"},{"key":"4262_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2019.09.025","volume":"138","author":"J Bar","year":"2019","unstructured":"Bar J, Ofek E, Barshack I, et al. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer. Lung Cancer. 2019;138:109\u201315.","journal-title":"Lung Cancer"},{"issue":"7","key":"4262_CR9","doi-asserted-by":"publisher","first-page":"105326","DOI":"10.1016\/j.esmoop.2025.105326","volume":"10","author":"C Catania","year":"2025","unstructured":"Catania C, Liu SV, Garassino M, et al. Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study. ESMO Open. 2025;10(7):105326.","journal-title":"ESMO Open"},{"issue":"4","key":"4262_CR10","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","volume":"16","author":"MG Oser","year":"2015","unstructured":"Oser MG, Niederst MJ, Sequist LV, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165\u201372.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4262_CR11","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41571-025-01029-7","volume":"22","author":"L-B Tang","year":"2025","unstructured":"Tang L-B, Peng Y-L, Chen J, et al. Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer. Nat Reviews Clin Oncol. 2025;22(8):546\u201365.","journal-title":"Nat Reviews Clin Oncol"},{"key":"4262_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2021.03.006","volume":"155","author":"W Wang","year":"2021","unstructured":"Wang W, Xu C, Chen H, et al. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study. Lung Cancer. 2021;155:20\u20137.","journal-title":"Lung Cancer"},{"key":"4262_CR13","doi-asserted-by":"publisher","first-page":"1153131","DOI":"10.3389\/fonc.2023.1153131","volume":"13","author":"J Ding","year":"2023","unstructured":"Ding J, Leng Z, Gu H, et al. Etoposide\/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study. Front Oncol. 2023;13:1153131.","journal-title":"Front Oncol"},{"issue":"4","key":"4262_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/1759-7714.12050","volume":"4","author":"Y Sun","year":"2013","unstructured":"Sun Y, Wang JW, Liu YY, et al. Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer. Thorac Cancer. 2013;4(4):440\u20138.","journal-title":"Thorac Cancer"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04262-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04262-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04262-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:27:39Z","timestamp":1782772059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04262-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4262"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04262-7","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The case was approved by the Ethics Committee of Hospital of Traditional Chinese Medicine of Guangdong Province (No: G2025-45). All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee(s) and with the Declaration of Helsinki and its subsequent amendments. Written informed consent was obtained from the patient for the publication of this case report and accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data published here are under the consent for publication. Written informed consent was obtained from the patient for the publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"288"}}